Alliance signed to study kinase drug targets.

2004 JAN 12 - (NewsRx.com & NewsRx.net) -- Cellular Genomics, Inc., (CGI), a chemical genetics-based biopharmaceutical company, announced that it has entered into a research collaboration with Eli Lilly and Company, under which CGI will apply its chemical genetics Analog Sensitive Kinase Allele (ASKA) technology to the study of kinase drug targets selected by Lilly.

"We are extremely pleased that Lilly has chosen to collaborate with CGI to further enhance their kinase drug discovery programs," said Louis Matis, president and CEO of CGI. "This marks the fifth collaboration we have established with a major pharmaceutical or biotechnology company based on our patented …